Ambit Biosciences
We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Our pipeline currently includes three programs, each discovered internally and each aimed at the inhibition of validated kinase targets. Our lead drug candidate, quizartinib, is a once-daily, orally administered FMS-like tyrosine kinase 3, or FLT3,
Basic Information
- Category: pharmaceutical industry
- Website: http://www.ambitbio.com
Documented Facts
- Inception (Wikidata): 2000-01-01 (Source 2: Wikidata Q16827821, revision 2534916015)
- Industry (Wikidata; date unspecified): pharmaceutical industry (Source 2: Wikidata Q16827821, revision 2534916015; Source 3: Wikidata label: Q507443, revision 2542338100)
- Headquarters location (Wikidata; date unspecified): San Diego (Source 2: Wikidata Q16827821, revision 2534916015; Source 4: Wikidata label: Q16552, revision 2555542477)
- Country (Wikidata; date unspecified): United States (Source 2: Wikidata Q16827821, revision 2534916015; Source 5: Wikidata label: Q30, revision 2556188301)
- Official website (Wikidata; date unspecified): http://www.ambitbio.com/ (Source 2: Wikidata Q16827821, revision 2534916015)
Evidence and Sources
- Ambit Biosciences — Official Website (official)
- Wikidata Q16827821, revision 2534916015 (knowledge-base)
- Wikidata label: Q507443, revision 2542338100 (knowledge-base)
- Wikidata label: Q16552, revision 2555542477 (knowledge-base)
- Wikidata label: Q30, revision 2556188301 (knowledge-base)
Citation Guidance
Explore pharmaceutical industry profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Ambit Biosciences.
- Canonical profile: https://brandsource.ai/brands/ambit-biosciences
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/ambit-biosciences/json-ld
- Citation profile API: https://brandsource.ai/api/brands/ambit-biosciences/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Our pipeline currently includes three programs, each discovered internally and each aimed at the inhibition of validated kinase targets. Our lead drug candidate, quizartinib, is a once-daily, orally administered FMS-like tyrosine kinase 3, or FLT3,
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 4 supporting sources linked.
- 5 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.